(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -1.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.7%.
Biontech Se's revenue in 2025 is $2,895,894,736.On average, 5 Wall Street analysts forecast BNTX's revenue for 2025 to be $515,851,798,994, with the lowest BNTX revenue forecast at $500,576,697,436, and the highest BNTX revenue forecast at $535,497,248,834. On average, 7 Wall Street analysts forecast BNTX's revenue for 2026 to be $644,532,303,106, with the lowest BNTX revenue forecast at $431,424,310,847, and the highest BNTX revenue forecast at $876,205,396,645.
In 2027, BNTX is forecast to generate $655,424,097,958 in revenue, with the lowest revenue forecast at $481,439,025,817 and the highest revenue forecast at $792,894,732,621.